Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022

Table of Contents

1 INTRODUCTION 16

1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.2.1 MARKETS COVERED 17
1.2.2 YEARS CONSIDERED IN THE REPORT 17
1.3 CURRENCY 18
1.4 LIMITATIONS 18
1.5 STAKEHOLDERS 18

2 RESEARCH METHODOLOGY 19

2.1 MARKET SIZE ESTIMATION 20
2.2 DATA TRIANGULATION 22
2.2.1 KEY DATA FROM SECONDARY SOURCES 24
2.2.2 KEY DATA FROM PRIMARY SOURCES 24
2.2.2.1 Key industry insights 25
2.2.3 ASSUMPTIONS FOR THE STUDY 25

3 EXECUTIVE SUMMARY 26
4 PREMIUM INSIGHTS 30

4.1 GLOBAL COMPANION DIAGNOSTICS MARKET OVERVIEW 30
4.2 COMPANION DIAGNOSTICS MARKET, BY INDICATION 31
4.3 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICES 31
4.4 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY 32

5 MARKET OVERVIEW 33

5.1 INTRODUCTION 34
5.2 MARKET DYNAMICS 34
5.2.1 DRIVERS 35
5.2.1.1 Improvements in regulatory guidelines 35
5.2.1.2 Growing need for targeted therapies 35
5.2.1.3 Rising cancer incidence worldwide 36
5.2.1.4 Increasing collaborations and partnerships for companion diagnostics test development 37
5.2.2 RESTRAINTS 37
5.2.2.1 Uncertain reimbursement scenarios in different regions 37
5.2.3 OPPORTUNITIES 39
5.2.3.1 Increasing demand for next-generation sequencing 39
5.2.3.2 Increasing number of clinical trials to boost the adoption of companion diagnostics 39
5.2.3.3 Emerging applications of companion diagnostics in other cancer indications, neurological disorders, infectious diseases, and cardiovascular diseases 41
5.2.4 CHALLENGE 41
5.2.4.1 Intellectual property rights protection issues 41

6 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 42

6.1 INTRODUCTION 43
6.2 ASSAY KITS AND REAGENTS 44
6.3 SOFTWARE & SERVICES 45

7 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY 47

7.1 INTRODUCTION 48
7.2 POLYMERASE CHAIN REACTION 49
7.3 IMMUNOHISTOCHEMISTRY 51
7.4 IN SITU HYBRIDIZATION 53
7.5 NEXT-GENERATION SEQUENCING 55
7.6 OTHER TECHNOLOGIES 57

8 COMPANION DIAGNOSTICS MARKET, BY INDICATION 59

8.1 INTRODUCTION 60
8.2 ONCOLOGY 61
8.2.1 BREAST CANCER 63
8.2.2 LUNG CANCER 63
8.2.3 COLORECTAL CANCER 63
8.2.4 MELANOMA 64
8.2.5 GASTRIC CANCER 64
8.2.6 OTHER CANCERS 64
8.3 NEUROLOGY 65
8.4 INFECTIOUS DISEASES 66
8.5 OTHER INDICATIONS 68

9 COMPANION DIAGNOSTICS MARKET, BY END USER 70

9.1 INTRODUCTION 71
9.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 72
9.3 REFERENCE LABORATORIES 74
9.4 OTHER END USERS 75
 

10 COMPANION DIAGNOSTICS MARKET, BY REGION 77

10.1 INTRODUCTION 78
10.2 NORTH AMERICA 79
10.2.1 U.S. 82
10.2.2 CANADA 85
10.3 EUROPE 88
10.3.1 GERMANY 92
10.3.2 FRANCE 94
10.3.3 U.K. 97
10.3.4 REST OF EUROPE 99
10.4 ASIA-PACIFIC 102
10.5 REST OF THE WORLD 106

11 COMPETITIVE LANDSCAPE 109

11.1 INTRODUCTION 109
11.2 MARKET RANKING ANALYSIS 109
11.3 COMPETITIVE LEADERSHIP MAPPING 110
11.3.1 VISIONARY LEADERS 110
11.3.2 INNOVATORS 110
11.3.3 DYNAMIC DIFFERENTIATORS 110
11.3.4 EMERGING COMPANIES 110
11.4 COMPETITIVE BENCHMARKING 112
11.4.1 STRENGTH OF PRODUCT PORTFOLIO (FOR 25 PLAYERS) 112
11.4.2 BUSINESS STRATEGY EXCELLENCE (FOR 25 PLAYERS) 113
*Top 25 companies analyzed for this studies are - ABBOTT LABORATORIES, INC., AGILENT TECHNOLOGIES, INC., BIOMÉRIEUX SA, DANAHER CORPORATION, ILLUMINA INC., MYRIAD GENETICS, INC., QIAGEN N.V., ROCHE DIAGNOSTICS, THERMO FISHER SCIENTIFIC, INC., ARUP LABORATORIES INC., SYSMEX CORPORATION, HOLOGIC, INC., NOVARTIS AG, ALMAC GROUP, ABNOVA CORPORATION INVIVOSCRIBE TECHNOLOGIES, INC., FOUNDATION MEDICINE, INC., BIOGENEX LABORATORIES, INC., LABORATORY CORPORATION OF AMERICA HOLDINGS, MEDICAL & BIOLOGICAL LABORATORIES CO., LTD, CLARITY PHARMACEUTICALS, RESEARCHDX, INC., NEOGENOMICS LABORATORIES, INC., JANSSEN DIAGNOSTICS, SIEMENS HEALTHCARE DIAGNOSTICS INC.

12 COMPANY PROFILES 114

(Overview, Business Overview, Business Strategy Excellence, Recent Developments)*
12.1 F. HOFFMANN-LA ROCHE AG 114
12.2 AGILENT TECHNOLOGIES, INC. 118
12.3 QIAGEN N.V. 122
12.4 THERMO FISHER SCIENTIFIC INC. 126
12.5 ABBOTT LABORATORIES, INC. 129
12.6 BIOMÉRIEUX SA 132
12.7 DANAHER CORPORATION 135
12.8 ILLUMINA, INC. 138
12.9 MYRIAD GENETICS, INC. 142
12.10 ARUP LABORATORIES INC. 145
12.11 SYSMEX CORPORATION 147
12.12 HOLOGIC INC. 150
12.13 NOVARTIS AG 153
12.14 ALMAC GROUP 155
12.15 ABNOVA CORPORATION 158
*Details on MarketsandMarkets view, Overview, Overview, Business Overview, Business Strategy Excellence, and Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX 160

LIST OF TABLES

TABLE 1 COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO WORLDWIDE 38
TABLE 2 PARTNERSHIPS AND COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS 39
TABLE 3 LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS 40
TABLE 4 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCT AND SERVICE,
2015–2022 (USD MILLION) 43
TABLE 5 COMPANION DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS, BY REGION, 2015–2022 (USD MILLION) 44
TABLE 6 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS, BY COUNTRY, 2015–2022 (USD MILLION) 44
TABLE 7 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS,
BY COUNTRY, 2015–2022 (USD MILLION) 45
TABLE 8 COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,
BY REGION, 2015–2022 (USD MILLION) 46
TABLE 9 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2015–2022 (USD MILLION) 46
TABLE 10 EUROPE: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES,
BY COUNTRY, 2015–2022 (USD MILLION) 46
TABLE 11 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 48
TABLE 12 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION 49
TABLE 13 COMPANION DIAGNOSTICS MARKET FOR PCR, BY REGION,
2015–2022 (USD MILLION) 49
TABLE 14 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2015–2022 (USD MILLION) 50
TABLE 15 EUROPE: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY,
2015–2022 (USD MILLION) 50
TABLE 16 COMPANION DIAGNOSTICS MARKET FOR IHC, BY REGION,
2015–2022 (USD MILLION) 51
TABLE 17 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IHC,
BY COUNTRY, 2015–2022 (USD MILLION) 52
TABLE 18 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY,
2015–2022 (USD MILLION) 52
TABLE 19 COMPANION DIAGNOSTICS MARKET FOR ISH, BY REGION,
2015–2022 (USD MILLION) 53
TABLE 20 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ISH,
BY COUNTRY, 2015–2022 (USD MILLION) 54
TABLE 21 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY,
2015–2022 (USD MILLION) 54
TABLE 22 COMPANION DIAGNOSTICS MARKET FOR NGS, BY REGION,
2015–2022 (USD MILLION) 55
TABLE 23 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NGS,
BY COUNTRY, 2015–2022 (USD MILLION) 56
TABLE 24 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY,
2015–2022 (USD MILLION) 56
TABLE 25 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,
BY REGION, 2015–2022 (USD MILLION) 57
TABLE 26 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2015–2022 (USD MILLION) 58
TABLE 27 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2015–2022 (USD MILLION) 58
TABLE 28 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2015–2022 (USD MILLION) 60
TABLE 29 COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE,
2015–2022 (USD MILLION) 61
TABLE 30 COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY REGION,
2015–2022 (USD MILLION) 62
TABLE 31 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY,
BY COUNTRY, 2015–2022 (USD MILLION) 62
TABLE 32 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY,
BY COUNTRY, 2015–2022 (USD MILLION) 62
TABLE 33 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISORDERS,
BY REGION, 2015–2022 (USD MILLION) 65
TABLE 34 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2015–2022 (USD MILLION) 65
TABLE 35 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2015–2022 (USD MILLION) 66
TABLE 36 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2015–2022 (USD MILLION) 66
TABLE 37 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2015–2022 (USD MILLION) 67
TABLE 38 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2015–2022 (USD MILLION) 67
TABLE 39 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION,
2015–2022 (USD MILLION) 68
TABLE 40 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2015–2022 (USD MILLION) 68
TABLE 41 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2015–2022 (USD MILLION) 69
TABLE 42 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 71
TABLE 43 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2015–2022 (USD MILLION) 72
TABLE 44 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2015–2022 (USD MILLION) 73
TABLE 45 EUROPE: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2015–2022 (USD MILLION) 73
TABLE 46 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES,
BY REGION, 2015–2022 (USD MILLION) 74
TABLE 47 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2015–2022 (USD MILLION) 74
TABLE 48 EUROPE: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES,
BY COUNTRY, 2015–2022 (USD MILLION) 75
TABLE 49 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION,
2015–2022 (USD MILLION) 75
TABLE 50 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2015–2022 (USD MILLION) 76
TABLE 51 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS,
BY COUNTRY, 2015–2022 (USD MILLION) 76
TABLE 52 COMPANION DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 78
TABLE 53 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 80
TABLE 54 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2015–2022 (USD MILLION) 80
TABLE 55 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 80
TABLE 56 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2015–2022 (USD MILLION) 81
TABLE 57 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY,
BY TYPE, 2015–2022 (USD MILLION) 81
TABLE 58 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 82
TABLE 59 U.S.: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 83
TABLE 60 U.S.: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 83
TABLE 61 U.S.: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2015–2022 (USD MILLION) 84
TABLE 62 U.S.: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY,
BY TYPE, 2015–2022 (USD MILLION) 84
TABLE 63 U.S.: COMPANION DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 85
TABLE 64 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 85
TABLE 65 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 86
TABLE 66 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2015–2022 (USD MILLION) 86
TABLE 67 CANADA: COMPANION DIAGNOSTICS MARKET SIZE FOR ONCOLOGY,
BY TYPE, 2015–2022 (USD MILLION) 87
TABLE 68 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 87
TABLE 69 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY,
2015–2022 (USD MILLION) 88
TABLE 70 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 90
TABLE 71 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 90
TABLE 72 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2015–2022 (USD MILLION) 90
TABLE 73 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY,
BY TYPE, 2015–2022 (USD MILLION) 91
TABLE 74 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 91
TABLE 75 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 92
TABLE 76 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 92
TABLE 77 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2015–2022 (USD MILLION) 93
TABLE 78 GERMANY: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY,
BY TYPE, 2015–2022 (USD MILLION) 93
TABLE 79 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 94
TABLE 80 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 94
TABLE 81 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 95
TABLE 82 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2015–2022 (USD MILLION) 95
TABLE 83 FRANCE: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY,
BY TYPE, 2015–2022 (USD MILLION) 96
TABLE 84 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 96
TABLE 85 U.K.: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 97
TABLE 86 U.K.: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 97
TABLE 87 U.K.: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2015–2022 (USD MILLION) 98
TABLE 88 U.K.: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY,
BY TYPE, 2015–2022 (USD MILLION) 98
TABLE 89 U.K.: COMPANION DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 99
TABLE 90 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 99
TABLE 91 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 100
TABLE 92 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2015–2022 (USD MILLION) 100
TABLE 93 ROE: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY,
BY TYPE, 2015–2022 (USD MILLION) 101
TABLE 94 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 101
TABLE 95 APAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 104
TABLE 96 APAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 104
TABLE 97 APAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2015–2022 (USD MILLION) 104
TABLE 98 APAC: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY, BY TYPE,
2015–2022 (USD MILLION) 105
TABLE 99 APAC: COMPANION DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 105
TABLE 100 ROW: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE,
2015–2022 (USD MILLION) 106
TABLE 101 ROW: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY,
2015–2022 (USD MILLION) 106
TABLE 102 ROW: COMPANION DIAGNOSTICS MARKET, BY INDICATION,
2015–2022 (USD MILLION) 107
TABLE 103 ROW: COMPANION DIAGNOSTICS MARKET FOR ONCOLOGY,
BY TYPE, 2015–2022 (USD MILLION) 107
TABLE 104 ROW: COMPANION DIAGNOSTICS MARKET, BY END USER,
2015–2022 (USD MILLION) 108
TABLE 105 RANK OF COMPANIES IN THE COMPANION DIAGNOSTICS MARKET, 2016 109

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 19
FIGURE 2 BOTTOM UP APPROACH 21
FIGURE 3 TOP DOWN APPROACH 21
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 22
FIGURE 5 MARKET DATA TRIANGULATION METHODOLOGY 23
FIGURE 6 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017 VS. 2022 26
FIGURE 7 GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017 VS. 2022 27
FIGURE 8 GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES,
2017 VS. 2022 27
FIGURE 9 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER, 2017 VS. 2022 28
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET 29
FIGURE 11 INCREASING DEMAND FOR TARGETED THERAPY IS BOOSTING THE COMPANION DIAGNOSTICS MARKET 30
FIGURE 12 ONCOLOGY SEGMENT IS ESTIMATED TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017 31
FIGURE 13 ASSAYS & REAGENTS SEGMENT IS ESTIMATED TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017 31
FIGURE 14 POLYMERASE CHAIN REACTION IS ESTIMATED TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017 32
FIGURE 15 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 34
FIGURE 16 INCREASING NUMBER OF NEW CANCER CASES WORLDWIDE,
2012 VS. 2015 VS. 2020 36
FIGURE 17 ASSAY KITS AND REAGENTS WILL CONTINUE TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 43
FIGURE 18 PCR WILL CONTINUE TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 48
FIGURE 19 ONCOLOGY SEGMENT TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 60
FIGURE 20 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES WILL CONTINUE TO DOMINATE THE COMPANION DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 71
FIGURE 21 GEOGRAPHIC SNAPSHOT: ASIA-PACIFIC MARKET TO REGISTER HIGHEST GROWTH DURING THE FORECAST PERIOD 78
FIGURE 22 NORTH AMERICAN COMPANION DIAGNOSTICS MARKET SNAPSHOT 79
FIGURE 23 EUROPEAN COMPANION DIAGNOSTICS MARKET SNAPSHOT 89
FIGURE 24 ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SNAPSHOT 103
FIGURE 25 COMPETITIVE LEADERSHIP MAPPING, 2017 111
FIGURE 26 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2016) 114
FIGURE 27 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2016) 118
FIGURE 28 QIAGEN N.V.: COMPANY SNAPSHOT (2016) 122
FIGURE 29 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2016) 126
FIGURE 30 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2016) 129
FIGURE 31 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2016) 132
FIGURE 32 DANAHER CORPORATION: COMPANY SNAPSHOT (2016) 135
FIGURE 33 ILLUMINA, INC.: COMPANY SNAPSHOT (2016) 138
FIGURE 34 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2016) 142
FIGURE 35 SYSMEX CORPORATION: COMPANY SNAPSHOT (2016) 147
FIGURE 36 HOLOGIC, INC.: COMPANY SNAPSHOT (2016) 150
FIGURE 37 NOVARTIS AG: COMPANY SNAPSHOT (2016) 153

当レポートのプレスリリースは発行されておりません。